MET vs NBIX · P/E 13, rev $38.23B vs P/E 45, rev $1.77B
MetLife Inc (MET) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
MetLife Inc (MET) is a insurance - life company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MET revenue for 2026-06-30 was $38.23B. Net income was $1.92B. MET currently screens at market cap $52.16B and trailing P/E 12.7.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MET currently screens at market cap $52.16B and trailing P/E 12.7. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MET and NBIX stock pages for the full models.
Not investment advice.